The $35 Calls and the 78% Pop: A Market, an FDA Filing, and the Question Hanging Over Both

On 18 June 2026, just before UniQure announced it was seeking FDA approval for a Huntington's disease gene therapy, an outsized batch of $35 calls on the stock — contracts expiring 17 July 2026 — changed hands. The stock finished the session up 78%. The flow was flagged publicly at 05:14 UTC, 06:53 UTC and again at 10:37 UTC by the market-data account Unusual Whales, whose "Good morning / Good night" cadence turned the alert into a same-day thread.

That sequence — a coordinated options print, a binary clinical headline, a vertical move in the underlying — is now a recognisable genre of American equity-market story. Each time it surfaces, the same two camps dig in. One treats the print as proof of insider trading. The other treats it as the ordinary plumbing of a derivatives market that prices information faster than newswires do. Both are partly right, and that is the problem.

The case for "someone knew"

The mechanical case is straightforward. UniQure ("QURE") is a small-cap clinical-stage biotech. Single-asset regulatory milestones — an FDA application, an adcom vote, a priority-review designation — move the stock by tens of percent in a session, sometimes more. Out-of-the-money calls that survive until expiry become extraordinarily convex bets on exactly those events. A $35 strike on a stock that closed meaningfully below that level, bought in size the same morning as the filing, pays off only if the share price jumps past the strike by mid-July. The optionality is a directional bet, not a hedge.

So when a trade of that shape prints in the hours before a discrete, catalyst-driven announcement, the prior probability of coincidence is low. It is lower still if the order flow is concentrated, if the contracts were opened rather than closed, and if the underlying has limited retail float. None of those facts are available in the thread that surfaced the alert, but the shape of the trade is consistent with all three.

The case for "the market is just fast"

The counter-read is older and more respectable. Listed options markets aggregate dispersed information from thousands of participants — specialists, market makers, hedge funds, banks running dispersion trades, retail platforms, systematic funds reading volatility surfaces. A regulatory milestone is often telegraphed: by trial-readout calendars, by management commentary on prior calls, by FDA action-date expectations, by the simple fact that a small-cap biotech with a binary asset is overdue for news. A patient, well-funded participant who has done the catalyst homework can position for the announcement without any private information at all.

That explanation is also incomplete. It accounts for some of the flow. It does not account for trades that look, in retrospect, almost perfectly calibrated to the moment the news crosses. Honest observers in the options community acknowledge as much: the same surveillance infrastructure that flags unusual prints is, by design, calibrated to detect the cases where the public-information story strains belief.

What the regulatory frame does — and does not — do

US options markets are supervised by FINRA and the SEC, with the responsibility for surveillance resting on the exchanges themselves and on FINRA's Order Audit Trail System. Insider trading in securities — including options — is a criminal matter under Section 10(b) of the Securities Exchange Act and Rule 10b-5. The SEC has, repeatedly, brought cases against traders who front-ran biotech catalysts using material non-public information, often obtained from insiders, clinicians or contracted analysts.

But the legal standard is narrow. The SEC has to show that the trader traded while in possession of a piece of material information that was both non-public and obtained in breach of a duty. That is a high bar. It is not the same as showing that a trade looked suspicious in hindsight. Thousands of unusually-shaped prints each year never become cases, and the public never learns the denominator.

Stakes, and what we still do not know

The stakes of any one trade are modest. The stakes of the regime are not. Retail participation in US options has grown sharply over the past five years; zero-commission platforms, fractional access, and the cultural normalisation of options as a "starter" product have moved what was once a professional market toward a mass audience. The same structural shift that gives ordinary investors access to convex biotech bets also makes the market harder to read, because order flow now blends genuine informed positioning with leveraged retail speculation and machine-generated market-making.

What the public sources surfaced on 18 June do not resolve. They do not say who bought the $35 calls. They do not say whether the SEC or FINRA has opened a review. They do not say whether the flow was a tip, a thesis, or a coincidence. They do establish that the print preceded the headline, that the print was large enough to flag, and that the move in the underlying was large enough to monetise. That is a recurring pattern in American biotech, and it deserves the same reflexive scrutiny whether or not this particular instance turns into an enforcement action.

The Monexus desk treats unusual-options-then-headline prints as a standing feature of small-cap biotech coverage, not as a one-off scandal. We will note the alert, the announcement and the price reaction, and we will resist both the reflex to call every print a crime and the reflex to dismiss every print as coincidence.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://x.com/unusual_whales/status/1234567890
• https://x.com/unusual_whales/status/1234567891
• https://x.com/unusual_whales/status/1234567892